What is it about?
This randomized controlled trial is to assess the potential effect of Tocovid, a tocotrienol-rich Vitamin E, derived from palm oil, in reducing the most common problem after coronary artery bypass grafting namely atrial fibrillation (POAF) which has been associated with a statistically significant increase in the incidence of stroke and also death. And also a statistically significant increase in ICU stay and a total hospital stay, which is translated into an increase in hospital cost, which ultimately is an economic burden to the country.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This study is important since it is the first time such a study is being conducted to determine the effectiveness of tocotrienol in reducing the most common complication after bypass surgery.
Perspectives
This paper reflects the dedication of our team at the National Heart Institute or more famously known as IJN - Institut Jantung Negara in Kuala Lumpur in executing such a meticulous study.
Dato' Dr Ahmad Farouk Musa
Monash University
Read the Original
This page is a summary of: A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis, Journal of Cardiothoracic Surgery, November 2021, Springer Science + Business Media,
DOI: 10.1186/s13019-021-01721-6.
You can read the full text:
Resources
Contributors
The following have contributed to this page
